| A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ... Nature medicine 18 (4), 521-528, 2012 | 664 | 2012 |
| Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants CA Eide, MS Zabriskie, SLS Stevens, O Antelope, NA Vellore, H Than, ... Cancer Cell 36 (4), 431-443. e5, 2019 | 165 | 2019 |
| Genomic landscape of neutrophilic leukemias of ambiguous diagnosis H Zhang, B Wilmot, D Bottomly, KHT Dao, E Stevens, CA Eide, V Khanna, ... Blood, The Journal of the American Society of Hematology 134 (11), 867-879, 2019 | 71 | 2019 |
| First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia HJ Ng, H Than, ECY Teo Thrombosis research 135 (1), 205-207, 2015 | 48 | 2015 |
| Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration W Xiang, JK Cheong, SH Ang, B Teo, P Xu, K Asari, WT Sun, H Than, ... Oncotarget 6 (32), 33769, 2015 | 43 | 2015 |
| SIRT5 is a druggable metabolic vulnerability in acute myeloid leukemia D Yan, A Franzini, AD Pomicter, BJ Halverson, O Antelope, CC Mason, ... Blood cancer discovery 2 (3), 266, 2021 | 41 | 2021 |
| The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations A Franzini, AD Pomicter, D Yan, JS Khorashad, SK Tantravahi, H Than, ... Blood advances 3 (20), 2949-2961, 2019 | 33 | 2019 |
| Nuclear–cytoplasmic transport is a therapeutic target in myelofibrosis D Yan, AD Pomicter, S Tantravahi, CC Mason, AV Senina, JM Ahmann, ... Clinical Cancer Research 25 (7), 2323-2335, 2019 | 32 | 2019 |
| Lysosome inhibition by mefloquine preferentially enhances the cytotoxic effects of tyrosine kinase inhibitors in blast phase chronic myeloid leukemia HL Yi, H Than, C Sng, MA Cheong, C Chuah, W Xiang Translational oncology 12 (9), 1221-1228, 2019 | 18 | 2019 |
| Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence SY Ong, YA Chin, H Than, CW Tan, ES Yap, WH Wong, HJ Ng Annals of hematology 96 (3), 525-527, 2017 | 17 | 2017 |
| SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia JR Sinnakannu, KL Lee, S Cheng, J Li, M Yu, SP Tan, CCH Ong, H Li, ... Leukemia 34 (7), 1787-1798, 2020 | 15 | 2020 |
| The EUTOS score is highly predictive for clinical outcome and survival in Asian patients with early chronic phase chronic myeloid leukemia treated with imatinib H Than, L Kuan, CH Seow, W Li, JC Allen Jr, C Chuah Blood, The Journal of the American Society of Hematology 120 (21), 3758-3758, 2012 | 12 | 2012 |
| Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells H Than, AD Pomicter, D Yan, LP Beaver, AM Eiring, WL Heaton, A Senina, ... Leukemia 34 (6), 1679-1683, 2020 | 9 | 2020 |
| BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients H Than, WK Lye, C Sng, JC Allen Jr, ST Ong, C Chuah Leukemia & lymphoma 60 (1), 234-237, 2019 | 8 | 2019 |
| A comprehensive study of current haemophilia care and outcomes in Singapore HJ Ng, J Lam, PL Koh, L Ho, CY Lim, M Akhbar Ali, D Mya, H Than, LP Ho, ... Haemophilia 21 (5), e428-31, 2015 | 8 | 2015 |
| Combining the allosteric ABL1 inhibitor asciminib (ABL001) with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 compound mutants CA Eide, MS Zabriskie, SL Savage, O Antelope, NA Vellore, H Than, ... Blood 134, 188, 2019 | 5 | 2019 |
| Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective H Than, Y Qiao, X Huang, D Yan, JS Khorashad, AD Pomicter, ... Leukemia 32 (9), 2049-2054, 2018 | 5 | 2018 |
| Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy JS Khorashad, SK Tantravahi, D Yan, CC Mason, Y Qiao, AM Eiring, ... Leukemia 30 (11), 2275-2279, 2016 | 3 | 2016 |
| SIRT5 as a therapeutic target in acute myeloid leukemia D Yan, AD Pomicter, WL Heaton, CC Mason, J Ahmann, A Senina, ... Blood 132, 907, 2018 | 2 | 2018 |
| Genetic profiling augments prognostic value of the EUTOS long-term survival score for disease-specific mortality in imatinib-treated asian chronic myeloid leukaemia patients H Than, WK Lye, CH Seow, CN Sng, JC Allen Jr, C Chuah Blood 128 (22), 3077, 2016 | 2 | 2016 |
